35
カタログ番号 | 製品名 | 別名 | ターゲット |
---|---|---|---|
T11761 | Tarlox-TKI | Kinase inhibitor-1 | EGFR |
Tarlox-TKI (Kinase inhibitor-1) is a pan-ErbB inhibitor, the active ingredient of Tarloxotinib, with antitumor activity.Tarlox-TKI inhibits NRG1 and suppresses HER2 mutants. | |||
T7104 | Dovitinib lactate | CHIR-258 lactate,TKI-258 lactate | VEGFR , FGFR , FLT , PDGFR , c-Kit |
Dovitinib lactate (TKI-258 lactate)(TKI258) lactate is a potent inhibitor of fibroblast growth factor receptor 3 (FGFR3) (IC50 :5 nM). | |||
T6193 | Dovitinib Dilactic Acid | Dovitinib (TKI-258) Dilactic Acid,TKI258 Dilactic acid | VEGFR , FGFR , FLT , c-Kit |
Dovitinib Dilactic Acid (Dovitinib (TKI-258) Dilactic Acid) is the Dilactic acid of Dovitinib, which is a multitargeted RTK inhibitor, mostly for class III (FLT3/c-Kit) with IC50 of 1 nM/2 nM, also potent to class IV (FG... | |||
T6289 | Dovitinib | TKI258,CHIR-258 | VEGFR , FGFR , FLT , PDGFR , c-Kit |
Dovitinib (CHIR-258) (TKI258, CHIR258) is a multitargeted RTK inhibitor, mostly for class III (FLT3/c-Kit, IC50: 1/2 nM), also effective to class IV (FGFR1/3) and class V (VEGFR1-4) RTKs (IC50: 8-13 nM), less potent to E... | |||
T8882 | Vodobatinib | K-0706 | Bcr-Abl |
Vodobatinib (K-0706) is a novel 3rd generation (3G) TKI effective against wild-type and mutated BCR-ABL1 with limited off-target activity. | |||
T8327 | ONO-7475 | Trk receptor , TAM Receptor | |
ONO-7475 is an inhibitor with high specificity for anexelekto and MER tyrosine kinase | |||
T6479 | Dovitinib lactate hydrate | Dovitinib (TKI258) Lactate,Dovitinib Lactate,TKI258 | VEGFR , FGFR , FLT , PDGFR , c-Kit |
Dovitinib lactate hydrate (TKI258) is the Lactate of Dovitinib, which is a multitargeted RTK inhibitor, mostly for class III (FLT3/c-Kit) with IC50 of 1 nM/2 nM, also potent to class IV (FGFR1/3) and class V (VEGFR1-4) R... | |||
T60076 | Oritinib | SH-1028 | EGFR |
Oritinib (SH-1028) is an inhibitor of EGFR with IC50s of 18, 0.7, 4, 0.1, 1.4 and 0.89 nM for EGFR (wt), EGFR (L858R), EGFR (L861Q), EGFR (L858R/T790M), EGFR (d746-750), EGFR (d746-750/T790M), respectively. Oritinib can ... | |||
T8491 | Vorolanib | CM082,X-82 | VEGFR , PDGFR |
Vorolanib (X-82) is an orally active VEGFR/PDGFR dual inhibitor. | |||
T8700 | TKIM | Potassium Channel | |
TKIM is a TWIK-related potassium channel 1 (TREK-1) inhibitor, binding to the pocket of the intermediate (IM) state of TREK-1. | |||
T70434 | Vabametkib | ||
Vabametkib, a potent hepatocyte growth factor receptor (HGFR) inhibitor, exhibits anti-proliferative effects on Hs746T cells and selectively inhibits c-Met with an IC50 value of 7 nM, showcasing its potential as an antin... | |||
T73334 | Larotinib | EGFR , IRAK , Tyrosine Kinases , BTK | |
Larotinib is an orally active, potent, and broad-spectrum tyrosine kinase inhibitor (TKI) with an IC50 of 0.6 nM for EGFR. | |||
T9601 | Tepotinib hydrochloride(1 : x) | c-Met/HGFR , P-gp , ABC | |
Tepotinib hydrochloride(1 : x) is an orally bioavailable, mesenchymal-epithelial transition (MET) TKI developed mainly for selected NSCLC patients with METex14 skipping mutations. | |||
T21322 | Mavelertinib | PF 06747775,PFE-X775,PF-06747775,PF-7775,PF 6747775,PF6747775 | EGFR |
Mavelertinib (PF-06747775) is an orally available, selective and potent EGFR tyrosine kinase (EGFR TKI) inhibitor with inhibitory effects on T790M/L858R and T790M/Del, and can be used in the study of oncology and respira... | |||
T11162 | EGFR-IN-8 | EGFR , c-Met/HGFR | |
T2147 | Nilotinib monohydrochloride monohydrate | Nilotinib (monohydrochloride monohydrate),AMN107 (monohydrochloride monohydrate) | Bcr-Abl , Autophagy |
Nilotinib monohydrochloride monohydrate (Nilotinib (monohydrochloride monohydrate)) is significantly potent BCR-ABL against, is a second generation tyrosine kinase inhibitor (TKI), and is active against many BCR-ABL muta... | |||
T4485 | Lazertinib | Lazertinib (YH25448),GNS-1480,YH25448 | EGFR |
Lazertinib (GNS-1480) is an effective, highly mutant-selective and irreversible EGFR-TKI with IC50 values of 1.7 nM, 2 nM, 5 nM, 20.6 nM and 76 nM for Del19/T790M, L858R/T790M, Del19, L85R and Wild type EGFR respectively... | |||
T16144 | MRX-2843 | UNC2371 | Others , FLT |
MRX-2843 (UNC2371) is a potent and orally active inhibitor of MERTK and FLT3(IC50s of 1.3 nM and 0.64 nM, respectively). | |||
T4605 | NT157 | IGF-1R , STAT | |
NT157 is a small molecule tyrphostin targeting IRS protein and has the potential to inhibit IGF-1R and STAT3 signaling pathways in TME cancer cells and stromal cells, resulting in decreased cancer cell survival. | |||
T62397 | Epitinib | ||
Epitinib is an orally active, selective, blood-brain barrier crossing epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). | |||
T34916 | Transtinib | ||
Transtinib is an effective and irreversible EGFR tyrosine kinase inhibitor (EGFR-TKI) that is active against L858R/T790M mutated NSCLC cell lines and xenografts. | |||
T68539 | CEP-11981 | BOL 303213X,ESK981 ; BOL 303213X,ESK981 | |
CEP-11981 (ESK981; BOL 303213X) is an orally active tyrosine kinase inhibitor (TKI) that targets TIE2, VEGFR1-3, and FGFR1. It exhibits potential anti-tumor and anti-angiogenic effects. | |||
T18638 | Boc-C5-O-C5-O-C6-Cl | PROTAC Linker 2 | Others |
Boc-C5-O-C5-O-C6-Cl (PROTAC Linker 2) is a chemical compound commonly employed as a linker in PROTAC applications. Its primary function is to connect a specific tyrosine kinase inhibitor (TKI) with the E3 recruiting liga... | |||
T72207 | Larotinib mesylate hydrate | ||
Larotinib mesylate hydrate is a potent, broad-spectrum, and orally active tyrosine kinase inhibitor (TKI), primarily targeting EGFR with an IC50 value of 0.6 nM. | |||
T36644 | Rezivertinib | ||
Rezivertinib (BPI-7711) is an orally active, highly selective and irreversible third-generation EGFR tyrosine kinase inhibitor (TKI) with potent activity against both common activation EGFR and resistance T790M mutations... | |||
T73104 | EGFR-IN-23 | ||
EGFR-IN-23, identified as compound 8 in WO2021244502A1, is a potent EGFR tyrosine kinase inhibitor (TKI) demonstrating an inhibitory concentration (IC50) of 8.05 nM against the BaF3/EGFR-DEL19/T790M/C797S cell line. | |||
T79711 | Antitumor photosensitizer-4 | Apoptosis | |
Antitumor Photosensitizer-4 (compound 10b), a conjugate of dasatinib and imatinib, serves as a potent tyrosine kinase inhibitor (TKI) targeting ABCG2. This photosensitizer (PS) induces apoptosis and reactive oxygen speci... | |||
T75015 | HX103 | ||
HX103, an epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI)-based fluorogenic probe, exhibits selective inhibition towards various EGFR mutations, including EGFR 19 del, EGFR L858R, EGFR wild type, ... | |||
T82971 | ARI-1 | ||
ARI-1 is a receptor tyrosine kinase-like orphan receptor 1 (ROR1) inhibitor that binds to ROR1's extracellular Frizzled domain, effectively inhibiting aberrant ROR1 expression linked to non-small cell lung cancer (NSCLC)... | |||
T74561 | JBJ-09-063 TFA | ||
JBJ-09-063 TFA is a mutant-selective allosteric EGFR inhibitor, displaying IC50 values of 0.147 nM for EGFR L858R, 0.063 nM for EGFR L858R/T790M, 0.083 nM for EGFR L858R/T790M/C797S, and 0.396 nM for EGFR L747S mutations... | |||
T72237 | JBJ-09-063 hydrochloride | ||
JBJ-09-063 hydrochloride is an EGFR inhibitor selective for mutants, demonstrating IC50 values of 0.147 nM, 0.063 nM, 0.083 nM, and 0.396 nM against EGFR L858R, EGFR L858R/T790M, EGFR L858R/T790M/C797S, and EGFR L747S, r... | |||
T1181L | Gefitinib hydrochloride | ||
Gefitinib hydrochloride (ZD1839 hydrochloride) is a potent and orally active EGFR tyrosine kinase inhibitor (EGFR-TKI) (IC 50 = 33 nM) that selectively inhibits EGF-stimulated tumor cell growth (IC 50 = 54 nM) and that b... | |||
T63939 | JBJ-09-063 | ||
JBJ-09-063 is a mutant-selective allosteric inhibitor of the epidermal growth factor receptor (EGFR), exhibiting potent inhibitory activity with half-maximal inhibitory concentrations (IC50s) of 0.147 nM for EGFR L858R, ... | |||
T35897 | ASK120067 | ||
ASK120067 is a potent and orally active inhibitor of EGFRT790M (IC50:0.3 nM) with selectivity over EGFRWT (IC50:6.0 nM). ASK120067 is a third-generation EGFR-TKI for the research of non-small cell lung cancer (NSCLC)[1]... | |||
T61358 | AKN-028 acetate | ||
AKN-028 acetate, a novel tyrosine kinase (TK) inhibitor, is a potent, orally active FMS-like receptor tyrosine kinase 3 (FLT3) inhibitor with an IC 50 value of 6 nM. AKN-028 acetate inhibits FLT3 autophosphorylation. AKN... |